“Neoadjuvant chemoradiotherapy followed by surgery is currently considered an important multimodality treatment option for patients with locally advanced esophageal or gastroesophageal junction cancer. Perioperative chemotherapy is an alternative multimodality treatment option for locally advanced gastroesophageal junction
adenocarcinoma.”

“Esophageal or gastroesophageal junction cancer patients with interval distant metastases after nCRT have a poor prognosis, with a median overall survival of 10 months after the diagnosis of the primary tumor. In comparison with 600 matched patients with synchronous distant metastases, patients with interval distant metastases had comparable overall survival from the moment of diagnosis of the primary tumor.”

Kroese TE, et al Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Thorac Surg. 2022 Feb;113(2):482-490. Free Full Text